Skip to Main Content

Paper Details

Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
JAMA Netw Open
1
2023
BRAF, BRAF V600E, BRAF V600E variant, BRAF variant, BRAF wildtype, BRAF wildtype tumors, CD45, CD45-positive cells, Cancer, Melanoma Brain Metastases, NF1, NRAS, NRAS variant, Patients, T-cell, V600E, V600E variant lesions, brain metastases, brain metastasis, cancer, immune cell populations, macrophage populations, melanoma brain metastases, melanoma brain metastasis, men, patient, patients, single, single nuclear RNA, tumor, tumors
Author NameAffiliation
Harish N VasudevanUniversity of California san francisco
Harish N VasudevanUniversity of California san francisco
Harish N VasudevanUniversity of California san francisco
Harish N VasudevanUniversity of California san francisco
William C ChenUniversity of California san francisco
Kanish MirchiaUniversity of California san francisco
Jacob S YoungUniversity of California san francisco
Lauren BoretaUniversity of California san francisco
Joanna J PhillipsUniversity of California san francisco
Joanna J PhillipsUniversity of California san francisco
Mariza DarasUniversity of California san francisco
Manish K AghiUniversity of California san francisco
David R RaleighUniversity of California san francisco
David R RaleighUniversity of California san francisco
David R RaleighUniversity of California san francisco
David R RaleighUniversity of California san francisco
Steve E BraunsteinUniversity of California san francisco
Steve E BraunsteinUniversity of California san francisco
  • 1 - 18

Datasets

Release 1.2